Pomalidomide: Phase III started

Celgene disclosed in its 3Q10 earnings that it began the double-blind, placebo-controlled Phase III RESUME trial to evaluate once-daily 0.5 mg oral pomalidomide in 210 patients with RBC-transfusion-de...